How to Get Rezdiffra (Resmetirom) in West Virginia

What Is Rezdiffra and Why Does It Matter for West Virginia Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on liver biopsy endpoints from the MAESTRO-NASH trial.

West Virginia carries one of the highest obesity prevalence rates in the United States. The CDC's 2023 Behavioral Risk Factor Surveillance System data placed the state's adult obesity rate at 40.6%, ranking it among the top three nationally 1. Obesity is the single strongest risk factor for MASH progression. An estimated 12 to 14% of adults with obesity develop MASH with clinically meaningful fibrosis, and fibrosis stage predicts liver-related mortality more reliably than any other histologic feature 2.

Before resmetirom, no pharmacotherapy carried an FDA indication for MASH. Treatment consisted of weight loss counseling, vitamin E (limited to non-diabetic patients), and off-label pioglitazone. Resmetirom works through a different mechanism: it is a thyroid hormone receptor-beta (THR-β) selective agonist that increases hepatic fat metabolism and reduces lipotoxic intermediates without systemic thyroid effects 3. This selectivity is what separates it from older thyroid analogs that caused cardiac and bone complications.

MAESTRO-NASH Trial Results: The Evidence Behind Approval

The key MAESTRO-NASH phase 3 trial (N=966) randomized adults with biopsy-confirmed NASH and fibrosis stages F1B through F3 to resmetirom 80 mg, 100 mg, or placebo once daily. At 52 weeks, 25.9% of patients on the 80 mg dose and 29.9% on the 100 mg dose achieved NASH resolution with no worsening of fibrosis, compared with 9.7% on placebo (P<0.001 for both comparisons) 3.

The fibrosis improvement endpoint told a similar story. Among patients receiving the 100 mg dose, 25.9% achieved at least a one-stage reduction in fibrosis without worsening of the NAFLD Activity Score, versus 14.2% on placebo 3.

LDL cholesterol dropped by approximately 16% in the 100 mg group. This is clinically relevant because MASH patients carry elevated cardiovascular risk, and cardiovascular events remain their leading cause of death 4. Diarrhea and nausea were the most common adverse events, occurring in 27% and 19% of patients on the 100 mg dose, respectively. Most gastrointestinal symptoms resolved within the first four weeks of treatment.

Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial, stated: "This is the first time we have a drug that hits both the inflammatory and fibrotic components of NASH in a meaningful proportion of patients, with a safety profile that supports long-term use" 3.

Who Qualifies for Rezdiffra in West Virginia?

The FDA label restricts Rezdiffra to adults with MASH and moderate-to-advanced hepatic fibrosis (stages F2, F3). Patients with decompensated cirrhosis (Child-Pugh B or C) are excluded. The label also specifies that approval was based on a surrogate endpoint (liver biopsy improvement), and continued approval may depend on confirmatory trials demonstrating clinical benefit.

A qualifying diagnosis requires either a liver biopsy showing a NAFLD Activity Score of 4 or higher with fibrosis stage F2 or F3, or a combination of validated noninvasive tests. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance supports using FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement between 8.0 and 13.9 kPa as consistent with significant fibrosis, alongside an elevated FIB-4 index above 1.3 5.

In practical terms, West Virginia clinicians typically confirm eligibility through this sequence:

1. FIB-4 calculation from routine labs (AST, ALT, platelet count, age)
2. FibroScan or MR elastography if FIB-4 exceeds 1.3
3. Liver biopsy when noninvasive results are indeterminate or when the payer demands histologic proof for prior authorization

Not every patient needs a biopsy. Several commercial insurers now accept noninvasive fibrosis assessment for prior authorization if the documentation package is complete.

How to Get a Prescription in West Virginia

West Virginia permits telehealth prescribing of Rezdiffra under the state's telehealth parity statute (W. Va. Code § 33-57). A valid prescriber-patient relationship can be established via synchronous audio-video visit, meaning patients in rural counties without nearby hepatology clinics can access the drug without traveling to Charleston, Morgantown, or Huntington.

Three pathways exist for obtaining a prescription:

In-person hepatology or gastroenterology visit. WVU Medicine, Charleston Area Medical Center (CAMC), and Marshall Health all have hepatology divisions with experience prescribing resmetirom. Referral from a primary care provider is typical but not always required by the practice.

Telehealth consultation. Licensed telehealth platforms operating in West Virginia can prescribe Rezdiffra if the provider holds an active West Virginia medical license and completes the required diagnostic workup. Lab orders and imaging can be completed at local facilities, with results reviewed during the telehealth encounter.

Primary care with specialist consultation. Some gastroenterologists offer eConsult models where a PCP manages the prescription after receiving a specialist's treatment plan. This model is growing in states with hepatology shortages.

West Virginia has approximately 1.8 gastroenterologists per 100,000 residents, compared with a national average of 4.0 per 100,000 6. Telehealth access meaningfully reduces the geographic barrier for patients in the state's southern and eastern counties.

Who Can Prescribe: MD vs. NP vs. PA

West Virginia law grants prescriptive authority to physicians (MD/DO), nurse practitioners (NP/APRN), and physician assistants (PA). All three provider types can legally prescribe Rezdiffra, though practical considerations differ.

NPs in West Virginia gained full practice authority under the 2016 legislative update (W. Va. Code § 30-7-15a), removing the previous collaborative agreement requirement after completing 3 to 600 hours of supervised practice 7. PAs still practice under a collaborative agreement with a supervising physician.

For prior authorization purposes, the prescriber's specialty matters more than their credential type. Insurers are more likely to approve a PA working under a hepatologist than a family medicine physician prescribing independently, because payer algorithms weight specialist involvement when reviewing specialty drug requests.

The practical recommendation: if a PCP identifies a patient who qualifies for resmetirom, the most efficient path is a single specialist consultation (in person or via telehealth) to generate the supporting documentation, followed by PCP-managed prescribing.

Labs and Monitoring Required Before and During Treatment

Before initiating Rezdiffra, clinicians should obtain a baseline panel that includes:

• Comprehensive metabolic panel (CMP) with hepatic function
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• TSH and free T4 (to exclude uncontrolled thyroid disease)
• CBC with platelet count (for FIB-4 calculation)
• HbA1c (MASH and type 2 diabetes overlap in 40 to 70% of patients)
• FibroScan or MR elastography (if not already completed)

The FDA prescribing information recommends checking hepatic function tests at baseline, during dose titration, and periodically thereafter. In clinical practice, most prescribers recheck liver enzymes at 4 weeks, 12 weeks, and then every 3 to 6 months.

Thyroid monitoring deserves specific attention. Resmetirom is THR-β selective, but TSH suppression has been observed at higher doses. The prescribing label recommends monitoring TSH at baseline and periodically during treatment. If TSH falls below 0.5 mIU/L, the clinical team should reassess the dose and thyroid status before continuing 8.

Gallbladder events, including cholelithiasis, were reported in MAESTRO-NASH at slightly higher rates in treated groups. Patients with known gallbladder disease should receive counseling about symptoms of biliary colic before starting therapy.

Prior Authorization and Insurance Coverage in West Virginia

West Virginia Medicaid does not currently cover Rezdiffra. This means that the roughly 600,000 West Virginians enrolled in Medicaid or CHIP as of 2025 cannot access the drug through their state plan without an individual exception or appeal.

Commercial insurers, including those offered through the ACA Marketplace, have begun adding Rezdiffra to specialty tiers. Typical prior authorization requirements include:

• Confirmed MASH diagnosis (biopsy or validated noninvasive assessment)
• Fibrosis stage F2 or F3 documented by imaging or histology
• Evidence of failed lifestyle modification (3 to 6 months)
• Prescriber attestation that the patient does not have decompensated cirrhosis
• Lab results within the past 90 days

The AASLD and the American Gastroenterological Association (AGA) published a joint payer guide in 2024 emphasizing that requiring liver biopsy as the sole diagnostic criterion creates an access barrier, particularly in states with limited procedural gastroenterology capacity 9. West Virginia fits this pattern. Advocacy from the prescribing team, including a letter of medical necessity referencing the MAESTRO-NASH trial data, improves approval rates.

Madrigal Pharmaceuticals offers the Rezdiffra Connect patient support program, which includes copay assistance for commercially insured patients and free drug programs for eligible uninsured or underinsured individuals. The manufacturer's website provides enrollment forms and a dedicated phone line for West Virginia patients.

Pharmacy Access: Specialty and 503A Compounding Options

Rezdiffra is classified as a specialty medication. Most patients receive it through specialty pharmacy distribution rather than a retail pharmacy counter. National specialty pharmacies that ship to West Virginia addresses include Accredo, CVS Specialty, and Optum Specialty Pharmacy.

West Virginia does permit 503A compounding pharmacies to compound resmetirom pursuant to a valid patient-specific prescription. However, a distinction matters here: 503A compounding is legal in the state, but the compounded product is not the same as the FDA-approved Rezdiffra tablet. The compounded version does not carry the same regulatory oversight, bioequivalence testing, or manufacturer support programs.

The AACE 2024 consensus statement on compounded medications noted: "Patients and prescribers should be aware that compounded thyroid hormone receptor agonists have not undergone the bioequivalence studies required of FDA-approved products, and dose-response predictability may differ" 10.

For most patients, the FDA-approved product through a specialty pharmacy is the recommended path. Compounding may serve as an alternative when cost is prohibitive and no patient assistance program eligibility exists, but the prescriber should document informed consent about the differences.

Shipping times to West Virginia addresses from major specialty pharmacies typically range from 2, 5 business days after the prescription is verified and any prior authorization is cleared. Cold chain requirements do not apply to resmetirom tablets, which are stored at room temperature.

Timeline: From First Visit to First Dose

A realistic timeline for a West Virginia patient starting from scratch:

• Week 1, 2: Initial consultation (telehealth or in-person), baseline labs ordered
• Week 2, 3: FibroScan or MR elastography completed at local facility
• Week 3, 4: Results reviewed, prescription submitted to specialty pharmacy
• Week 4, 6: Prior authorization processed; appeals if denied
• Week 5, 7: Medication shipped and received

The bottleneck is almost always prior authorization. Denials are common on first submission, particularly when documentation is incomplete. The fastest path is a complete submission packet on the first attempt: diagnosis, fibrosis staging, lab results, failed lifestyle modification documentation, and a letter of medical necessity citing MAESTRO-NASH data.

For patients using Madrigal's bridge program, interim supply may arrive within 5, 7 business days of enrollment verification, covering the gap during PA processing.

Cost Considerations Without Insurance Coverage

The wholesale acquisition cost (WAC) of Rezdiffra is approximately $47,400 per year for the 100 mg dose. This price point places it in the same tier as other specialty hepatology drugs.

Patients without coverage have several options to reduce out-of-pocket costs:

• Madrigal's patient assistance program (income-based eligibility, typically below 400% of the federal poverty level)
• Copay cards for commercially insured patients (may reduce copay to $0, $25 per month)
• State pharmaceutical assistance: West Virginia does not currently operate a state-funded specialty drug assistance program, but the WV DHHR can direct patients to manufacturer programs
• 503A compounding (lower cost but with the caveats discussed above)

The Endocrine Society's 2024 policy statement on drug pricing noted that "specialty drug costs for metabolic liver disease disproportionately affect patients in states with high obesity prevalence and limited Medicaid formulary coverage," naming West Virginia as one of five states where access gaps are most pronounced 11.